CLASS II Drug recall · Reported 10 Oct 2018 · FDA Enforcement Report

Elelyso (taliglucerase alfa) for injection, single-use vial recalled

Pfizer is recalling Elelyso (taliglucerase alfa) for injection, single-use vial, distributed nationwide in the US. The recall was initiated on 19 Sep 2018 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot S91616
NDC0069-0106
Quantity recalled12,416 vials

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0005-2019
FDA event ID
81050
Recalling firm
Pfizer, New York, NY
Brand
Elelyso
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Classification
Class II
Status
Terminated
Recall initiated
19 Sep 2018
FDA classified
2 Oct 2018
Reported
10 Oct 2018
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Foreign Material

Timeline

19 Sep 2018Recall initiated by company
2 Oct 2018Classified by FDA+13 days
10 Oct 2018Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Foreign material recalls cover pieces of metal, plastic, glass, wood or other objects that got into the product during processing and could cause injury if eaten.

Product as listed by the FDA

Elelyso (taliglucerase alfa) for injection, 200 units/vial, single-use vial, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, NDC 0069-0106-01

Where it was distributed

U.S.A. nationwide. The following countries received product from Lot S91616: Albania, South Africa, Israel, Afghanistan, Rwanda, Botswana, Zimbabwe and Iraq as part of the Compassionate Use Program.

Nationwide

Questions about this recall

Why was it recalled?

Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.

Which lots are affected?

Lot S91616

Where was it sold?

U.S.A. nationwide. The following countries received product from Lot S91616: Albania, South Africa, Israel, Afghanistan, Rwanda, Botswana, Zimbabwe and Iraq as part of the Compassionate Use Program.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Pfizer

All 127

Other Taliglucerase Alfa recalls

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIElelyso (taliglucerase alfa) for injections recalled by PfizerElelysoPfizerForeign MaterialNationwide